Customer Center
Login | Register


Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Read More

Research & Applied Markets

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
Read More

Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
Learn More

Luminex® Blog

How to Multiplex Analysis of Autoimmune Biomarkers

At Protagen, scientists enlist xMAP® Technology to characterize autoantibodies

Multiplex analysis of autoantibodies is an effective way to understand autoimmune disease, discover important biomarkers, and stratify patients into subgroups, according to Hans-Dieter Zucht, Head of Technology at Protagen.

Continue Reading >

xMAP® Technology Overview

Luminex xMAP® Technology Overview


xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.

Watch more videos >

Luminex on Twitter

Fact 3: In some countries, as many as four in 1,000 live births are affected by GBS. #FollowTheFacts #GBSaware…
h J R
Have you submitted your abstract for your #xMAPConnect poster? Don't miss out on your chance! Learn more here:…
h J R
Does multiplexing seem too complex? Hans-Dieter Zucht of #Protagen breaks it down, from establishing panels to maki…
h J R

Latest News

June 13
Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay

May 18
Luminex Corporation to Present at Upcoming Healthcare Investor Conferences

May 18
Luminex Corporation Declares Second Quarter Cash Dividend

May 7
Luminex Corporation Reports First Quarter 2018 Financial Results

April 16
Luminex Corporation First Quarter Earnings Release Scheduled for May 7, 2018


2-5 September
Amsterdam, Netherlands

Microbe UK
21-23 September
Sheffield, UK

World Vaccine Congress
29-31 October
Lisbon, Portugal